Dr. Lucio Mango confers a degree in Medicine at “La Sapienza“ University in Rome, Italy (1974). He is a specialist in Nuclear Medicine (1977) and Endocrinology (1980) in the same University and also Director of Nuclear Medicine Unit at the “S.Camillo-Forlanini” General Hospital in Rome (from 1999 up to now).
Dr. Lucio Mango is also Scientific Director of the 2nd level Master(Ph.D.) on Health Management at the University of International Studies (UNINT), in Rome (from 20013 up to now). He is now working on Nuclear Therapy research n Oncology and Endocrinology.
Dr. Lucio Mango is a Professor in Nuclear Medicine at “La Sapienza“ University (since 1997-now) in Rome and of Health Management at the University of International Studies (from 2010-now), in Rome. He had published up to 180 papers in Nuclear Medicine, Oncology, Cardiology, Endocrinology, Health and Risk Management, and Ethics, and He also serves as an editorial member for various international journals.
- Improving the dose-myelotoxicity correlation in radiometabolic therapy of bone metastases with Sm-153-EDTMP.
- Dosimetry of bone metastases in targeted radionuclide therapy with alpha-emitting 223Ra-dichloride.
- Differentiated Thyroid Carcinoma and Late Onset of Lung Distant Metastasis. A Case Report.
- Lymphoscintigraphy for the evaluation of limb lymphatic flow disorders: Report of technical procedural standards from an Italian Nuclear Medicine expert panel.
- Dosimetry for molecular radiotherapy.
- Conventional Cardiological Nuclear Diagnostics in the Third Millennium.
- Towards a dose-response correlation in radioiodine therapy of hyperthyroidism from nodular thyroid disease.
- 330. 223Ra therapy of bone metastases for castration-resistant prostate cancer (CRPC): Lesion dosimetry and follow-up for a large group of patients.
- Prostate Cancer Bone Metastases 223 Ra-Dichloride Therapy: Theranostics and Dosimetry.
- Theranostic approach in lung cancer bone metastases.
- Skills Required to Head Physician for the Management of Staff. Emotions in the Organizational Context.
- 223Ra-dichloride in castration-resistant prostate cancer (CRPC) with bone metastases: a still unexplored resource.
- Dosimetry-Based Consideration on Remission and Relapse after Therapy with 223Ra-Dichloride in Castration-Resistant Prostate Cancer (CRPC) with Bone Metastases. A Case Report.
- Search Sentinel Lymph Node in Melanoma: SPECT/CT Added Value. A Case Report.
- Clinical Governance: Application in Nuclear Medicine.
- B7Radium-223 with concomitant bone-targeting agents in metastatic castration-resistant prostate cancer (CRPC) patients treated in an international early access program (EAP).
- B8Changes in alkaline phosphatase (ALP) dynamics and overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients treated with radium-223 in an international early access program (EAP).
- Dose-response correlation in radioiodine therapy of hyperthyroidism from nodular thyroid disease.
- Case report of a patient studied by brain SPECT and several neuropsychological tests for assessing correlation between drugs abuse, cognitive impairment and onset of psychotic disorder.
- Relazione medico-paziente in Medicina Nucleare.
- Lymphoscintigraphy and clinic.
- Neuroendocrine Tumors (NET) and Nuclear Medicine.
- Hybrid Technology: From Cars to Diagnosis.
- Gamma camera calibrations for the Italian multicentre study for lesion dosimetry in 223 Ra therapy of bone metastases.
- Theranostics: A Unique Concept to Nuclear Medicine.
- Linfoscintigrafia e sue integrazioni. Importanza del Transport Index.
- Lesion dosimetry for 223Ra therapy of bone metastases from castration-resistant prostate cancer: patients eligibility criterion and update of dosimetric assessments.
- Analysis of overall survival by number of radium-223 injections received in an international expanded access program (iEAP).
- Study of inter-fraction variability of absorbed dose to bone metastases and follow-up for a patient who underwent 223Ra-dichloride therapy.
- Lesions dosimetry for 223Ra therapy of bone metastases from castration-resistant prostate cancer.
- A case report of image-based dosimetry of bone metastases with Alpharadin (223Ra-dichloride) therapy: inter-fraction variability of absorbed dose and follow-up.
- Feasibility of 223Ra quantitative imaging for lesion dosimetry.
- Feasibility of 223 Ra imaging for clinical purpose.
- Correlation between drugs abuse, cognitive impairment and onset of a psychotic disorder: a pilot study using SPECT and neuropsychological assessment.
